Author: flexprd

Hwang and Kesselheim Analyze the Impact of Taxing Drug Price Spikes

In a recent post on the IVI-sponsored Health Affairs featured blog series,Thomas Hwang and Aaron Kesselheim examine proposed new legislation taxing manufacturers of pharmaceuticals with medications exhibiting significant pricing spikes. Hwang and Kesselheim break down the criteria for the tax, and also offer some insight into potential policy implications. Read the full article here. About the Health […]

Review of Key Provisions of FDA’s User Fee Reauthorization Bill

In the latest post on the IVI-sponsored Health Affairs featured blog series, Rachel Sachs addresses key provisions of the FDA’s proposed user fee reauthorization bill. Included in her assessment are details of new language changes and amendments added to the bill, as well as a look forward to potential obstacles to the bill’s final passage. Read […]

Examining Policies to Promote Development of Antimicrobial Drugs

In the latest post on the IVI-sponsored Health Affairs featured blog series, Seth Seabury and Neeraj Sood examine the challenges to addressing the significant threat that antimicrobial resistant infections pose to human health. In their commentary, Seabury and Sood focus on three of the most commonly proposed policies to promote the development of new antimicrobials: market […]

What Matters Most to Patients

In a post on the IVI-sponsored Health Affairs blog series,Josh Seidman, Margaret Anderson, Domitilla Masi, Melea Atkins and Maureen Japha examine the role of patient perspectives in assessing value in healthcare, focusing on the Avalere-FasterCures Patient-Perspective Value Framework as an example of progress toward a more patient-centered approach to value assessment. Read the full article […]

Baumgardner Participates in Becker Friedman Institute’s Health Care Reform Panel

On May 22nd, James Baumgardner, who provides legislative policy expertise as a part of IVI’s Scientific Advisory Group, was an invited panelist for a forum at The University of Chicago’s Becker Friedman Institute. On the panel, titled “The Economic Consequences of Health Care Reform,” Baumgardner applied his past experience as a 20-year veteran of the […]

Manolis, Good and Shrank Address Abuse-Deterrent Opioids

In the latest post on the IVI-sponsored Health Affairs blog series, Chronis Manolis, C. Bernie Good and William Shrank discuss current approaches to curbing rampant opioid abuse, including the mandating of coverage for abuse-deterrent opioids. The authors make the case that this tactic would be non-effective, costly and would distract from arriving at more comprehensive solutions […]

Carrier and Shadowen Propose Fixes for Pharma “Product Hopping”

In a recent post on the IVI-sponsored Health Affairs blog series, Michael Carrier and Steve Shadowen examine the practice of “product hopping,” in which drug manufacturers can delay a generic introduction through product reformulation. In addition to presenting some of the prevailing issues before the courts, the authors also propose a new framework to keep the […]

Light Addresses the Pharma “Free Rider” Myth (in Response to Yu, Helms, and Bach)

In the latest post on the the IVI-sponsored Health Affairs blog series, Donald Light offers a response to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach focusing on the excess of US drug pricing over prices in other developed countries. Light argues that the myth of the “foreign free-rider,” […]

Grabowski and Manning Respond to a Recent Post by Yu, Helms, and Bach

In a post on the the IVI-sponsored Health Affairs blog series, Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach on the subject of drug pricing. In their rebuttal, Grabowski and Manning caution that the premise of the earlier blog post […]